Search Results - "Baldus, John E"
-
1
Discovery of N‑(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)‑5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)‑2H‑tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis
Published in Journal of medicinal chemistry (14-01-2016)“…Matrix metalloproteinase-13 (MMP-13) is a zinc-dependent protease responsible for the cleavage of type II collagen, the major structural protein of articular…”
Get full text
Journal Article -
2
Continued exploration of the triazolopyridine scaffold as a platform for p38 MAP kinase inhibition
Published in Bioorganic & medicinal chemistry letters (15-01-2010)“…The structure based drug design, synthesis and structure–activity relationship of a series of C6 sulfur linked triazolopyridine based p38 inhibitors are…”
Get full text
Journal Article -
3
Discovery of 5-substituted- N-arylpyridazinones as inhibitors of p38 MAP kinase
Published in Bioorganic & medicinal chemistry letters (15-05-2010)“…The synthesis, structure–activity relationship and modeling of a series of 5-substituted- N-aryl pyridazinone based p38α inhibitors are described. In comparing…”
Get full text
Journal Article -
4
Discovery of N -(4-Fluoro-3-methoxybenzyl)-6-(2-(((2 S ,5 R )-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2 H -tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis
Published in Journal of medicinal chemistry (14-01-2016)Get full text
Journal Article